CJC-1295 (No DAC) 5mg | 10-Vial Kit
50mg Total · ~30 min t½
QSC Peptides · Mod GRF 1-29
$230Buy →
≥99% Pure · COA
Both CJC-1295 and Ipamorelin from QSC Peptides stimulate GH secretion — but via completely different receptor systems, with different half-lives and selectivity profiles. Understanding the distinction is fundamental to GH axis research design.
| Property | CJC-1295 (No DAC) | CJC-1295 (With DAC) | Ipamorelin |
|---|---|---|---|
| Drug Class | GHRH Analog | GHRH Analog (long-acting) | GH Secretagogue |
| Receptor Target | GHRHR | GHRHR | GHSR-1a (Ghrelin-R) |
| Half-Life | ~30 minutes | 6–8 days | ~2 hours |
| Sequence | Modified GHRH(1-29) | Mod GHRH(1-29) + DAC | Aib-His-D-2Nal-D-Phe-Lys-NH₂ |
| Molecular Weight | ~3367 Da | ~3862 Da | 711.9 Da |
| GH Stimulation | GHRHR-mediated | GHRHR-mediated | GHSR-1a-mediated |
| Cortisol Effect | None | None | None |
| Prolactin Effect | None | None | None |
| Appetite Effect | None | None | None |
| QSC Peptides Price (10-vial) | From $230 | From $290 | From $190 |
* Data for research reference. All products by QSC Peptides (qscpeptide.com).
CJC-1295 and Ipamorelin both drive GH secretion from pituitary somatotrophs — but via entirely different receptor systems operating in parallel on the same cells.
CJC-1295 binds the GHRH receptor (GHRHR), a Gs-protein-coupled receptor. Activation raises intracellular cAMP via adenylyl cyclase, activates PKA, phosphorylates CREB, and drives GH gene transcription. CJC-1295 also increases GH granule priming (increasing the releasable pool). The No DAC form (~30 min t½) produces clean pulsatile responses; the DAC form (~6–8 days) provides sustained GHRHR occupancy.
Ipamorelin binds GHSR-1a (ghrelin receptor), a Gq-protein-coupled receptor. Activation drives PLC → IP3 → intracellular Ca²⁺ → GH granule exocytosis. Critically, Ipamorelin also activates GHSR-1a on hypothalamic neurons, suppressing somatostatin tone — which amplifies pituitary GH responsiveness to all stimuli, including CJC-1295.
The GHRHR and GHSR-1a pathways are independent and complementary. GHRHR drives GH synthesis and granule priming; GHSR-1a drives exocytosis and suppresses somatostatin. Activating both simultaneously produces additive to synergistic GH pulse amplification — more than either alone. This is why QSC Peptides offers the pre-blended CJC-1295 + Ipamorelin GH Stack vial.
Research Protocol Note: For maximum GH pulse amplitude in dual-receptor research, QSC Peptides offers the pre-blended CJC-1295 (No DAC) + Ipamorelin vial in 10mg and 20mg concentrations as a convenient single-vial GH stack.
Use Both Together (GH Stack): For maximum GH axis stimulation targeting both GHRHR and GHSR-1a simultaneously, use the QSC Peptides CJC-1295 + Ipamorelin pre-blended vial — available in 10mg and 20mg concentrations in 10-vial and 20-vial kits.
QSC Peptides · Mod GRF 1-29
QSC Peptides · Long-acting
QSC Peptides
QSC Peptides
QSC Peptides
QSC Peptides